Scleroderma Therapeutics Market Analysis

Route of Administration (Oral, Injectable, Other Routes of Administration)

By route of administration, the oral segment is set to account for scleroderma therapeutics market share of more than 69.8% by the end of 2037. The growth of the segment is attributed to convenience of oral administration and greater patient compliance leading to increasing adoption of the oral route for administration. Methotrexate such as Trexall, Rheumatrex, Otrexup, Rasuvo, and CellCept (Mycophenolate Mofetil) are oral drugs administered to treat scleroderma. Immunosuppressants and anti-fibrotic agents are administered orally to manage scleroderma by slowing its progression.

The segment growth can be attributed to its accessibility compared to the other routes of administration. Additionally, the oral segment of the global scleroderma therapeutics sector can benefit from advancements in new formulations leading to targeted oral therapies that can minimize side effects. In May 2024, Azurity Pharmceuticals Inc., announced approval of their mycophenolate mofetil oral suspension (MYHIBIN) by the FDA. A favorable regulatory ecosystem is positioned to boost the continued growth of the oral segment by the end of the forecast period.

The injectable segment of the market is poised to increase its revenue share during the forecast period. The growth of the segment is attributed to rising adoptions to treat severe cases of systemic sclerosis with rapid disease progression. This route of administration offers rapid therapeutic effects for patients with life-threatening complications such as pulmonary hypertension which occurs in up to 40% of patients suffering from scleroderma as per the University of Michigan Health. The segment is positioned for further growth by the end of the forecast period with advancements in biologics. For instance, in September 2024, the FDA approved Roche’s injectable version of multiple sclerosis therapy under the brand name Ocrevus.

Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Other Drug Classes)

In scleroderma therapeutics market, immunosuppressors segment is expected to account for revenue share of more than 31.5% by the end of 2037. The segment’s growth is attributed to the increasing adoption of immunosuppressors to control the immune response, as scleroderma is an autoimmune disease. Immunosuppressors are used to slow disease progression and reduce kidney inflammation in patients. The demand for immunosuppressors is growing with the rising prevalence of autoimmune diseases globally.

The increasing research on the treatment of autoimmune disease is positioned to continue to growth of the segment by the end of the forecast period. For instance, in June 2023, the Johns Hopkins Medicine Team suggested microparticle-delivered therapy is a significant step in the treatment of autoimmune disease, and microparticles can be designed to deliver specific therapeutic agents, i.e., immunosuppressors to precise locations in the body.

Our in-depth analysis of the global market includes the following segments: